iShares S&P GSCI Commodity-Indexed Trust ETF vs Medtronic PLC — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $31.06, while Medtronic PLC trades at $83.98 (market cap $103.01B). The key difference: Medtronic PLC pays a 3.58% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| GSG | MDT | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $105.35 |
52-Week Low | $22.06 | $73.75 |
Market Cap | — | $103.01B |
Enterprise Value | — | $121.75B |
Dividend Yield | — | 3.58% |
Signals from Pluang's Aura AI — not financial advice
GSG trades at $31.00, up 1.57% today, with strong bullish technical signals from moving averages and ADX indicators, though RSI levels suggest overbought conditions. The stock's support and resistance levels are consolidated at $31.00, indicating a pivotal price point. Recent news highlights commodities as a key market theme, which may benefit GSG given its focus.
The outlook for GSG is cautiously optimistic, driven by bullish technical trends and positive sentiment around commodities. Risks include potential overbought corrections and reliance on commodity market stability. Investment opportunities hinge on sustained commodity demand, but investors should monitor earnings fundamentals for validation.
Medtronic (MDT) trades at $79.30, down 5.11% over 24 hours, with technical indicators showing bearish momentum. Fundamentally, the company reported strong earnings beats for three consecutive quarters and maintains solid profitability with a 13.2% net income margin. Recent news highlights the completion of the Scientia Vascular acquisition and bullish analyst coverage citing undervaluation and growth in cardiovascular and neuroscience segments.
The stock presents a compelling opportunity with a consensus price target of $97.50 representing 23% upside, supported by 58% analyst buy ratings. Key risks include increasing debt-to-asset ratios (31.11% in 2025) and margin pressures from tariffs and foreign exchange. The dividend aristocrat offers a near-decade high yield with consistent dividend growth.
Trailing returns across standard periods
Latest headlines on both assets
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →